ArticleViruses2010
RNA replicons - a new approach for influenza virus immunoprophylaxis.
Article in Viruses, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Lipid nanoparticle-based mRNA platforms for mucosal HIV vaccines: formulation advances, immune mechanisms, and translational pathways.Archives of microbiology · 2025Review
- Article
- mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy.Biomarker research · 2024Review
- mRNA vaccines: a new era in vaccine development.Oncology research · 2024Review
- mRNA vaccine in cancer therapy: Current advance and future outlook.Clinical and translational medicine · 2023Review
- The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination.Vaccines · 2021Review
- mRNA vaccine for cancer immunotherapy.Molecular cancer · 2021Review
- Semliki Forest Virus replicon particles production in serum-free medium BHK-21 cell cultures and their use to express different proteins.Cytotechnology · 2019Article
- A COL1A1 Promoter-Controlled Expression of TGF-β Soluble Receptor Inhibits Hepatic Fibrosis Without Triggering Autoimmune Responses.Digestive diseases and sciences · 2018Article
- Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids.Molecular therapy. Nucleic acids · 2018Article
- Virus replicon particle vaccines expressing nucleoprotein of influenza A virus mediate enhanced inflammatory responses in pigs.Scientific reports · 2017Article
- Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.Journal of virology · 2016Article
- Use of Recombinant Virus Replicon Particles for Vaccination against Mycobacterium ulcerans Disease.PLoS neglected tropical diseases · 2015Article
- Reprint of: Coronavirus reverse genetic systems: infectious clones and replicons.Virus research · 2014Article
- A cationic nanoemulsion for the delivery of next-generation RNA vaccines.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Coronavirus reverse genetic systems: infectious clones and replicons.Virus research · 2014Review
- Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles.International journal of nanomedicine · 2014Review
- Development of porcine respiratory and reproductive syndrome virus replicon vector for foot-and-mouth disease vaccine.Clinical and experimental vaccine research · 2014Article
- RNA replicon delivery via lipid-complexed PRINT protein particles.Molecular pharmaceutics · 2013Article
- Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ.Vaccines · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA replicons are derived from either positive- or negative-strand RNA viruses. They represent disabled virus vectors that are not only avirulent, but also unable to revert to virulence. Due to autonomous RNA replication, RNA replicons are able to drive high level, cytosolic expression of recombinant antigens stimulating both the humoral and the cellular branch of the immune system. This review provides an update on the available literature covering influenza virus vaccines based on RNA replicons. The pros and cons of these vaccine strategies will be discussed and future perspectives disclosed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.